Core Viewpoint - Sinovac Biotech Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities International as the exclusive sponsor [1] Company Summary - Sinovac Biotech Ltd. is seeking to go public on the Hong Kong Stock Exchange [1] - The exclusive sponsor for this listing is CITIC Securities International [1]

Core Viewpoint - The company has submitted an application for the issuance of H-shares and listing on the Hong Kong Stock Exchange on November 6, 2025, indicating a strategic move to access international capital markets [1] Group 1 - The application materials submitted are in draft form and may be updated or revised as necessary [1] - The issuance, if implemented, will be limited to eligible foreign investors and qualified domestic investors who are authorized to conduct overseas securities investments according to Chinese laws and regulations [1]

Core Viewpoint - The company, Sinovac Biotech (688136.SH), has submitted an application for issuing H-shares and listing on the Hong Kong Stock Exchange on November 6, 2025 [1] Group 1 - The application materials were published on the Hong Kong Stock Exchange website on the same day [1] - The materials were prepared in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [1] - The information contained in the application is a draft version and may be updated or revised [1]

Group 1 - Company: Sinovac Biotech Ltd. has submitted a listing application to the Hong Kong Stock Exchange [1]

Core Viewpoint - The stock of Kexing Pharmaceutical has experienced a decline of 5.09%, currently trading at 38.38 CNY per share, with a total market capitalization of 7.724 billion CNY [1] Company Overview - Kexing Biological Pharmaceutical Co., Ltd. is located in Jinan, Shandong Province, and was established on August 22, 1997. The company went public on December 14, 2020. Its main business involves the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations [1] - The revenue composition of the company is primarily from pharmaceutical products, accounting for 97.38%, while other sources contribute 2.62% [1] Fund Holdings - According to data, one fund under Southern Fund has a significant holding in Kexing Pharmaceutical. The Southern All-Weather Strategy Mixed (FOF) A (005215) held 120,000 shares in the third quarter, representing 0.6% of the fund's net value, making it the third-largest holding [2] - The estimated floating loss for the fund today is approximately 247,200 CNY [2] Fund Performance - The Southern All-Weather Strategy Mixed (FOF) A (005215) was established on October 19, 2017, with a current scale of 641 million CNY. Year-to-date, it has achieved a return of 7.41%, ranking 260 out of 342 in its category. Over the past year, the return is 9.2%, ranking 237 out of 324, and since inception, the return is 48.9% [2] Fund Management - The fund is managed by Xia Yingying and Li Wenliang. Xia has a tenure of 7 years and 362 days, with a total asset scale of 1.176 billion CNY and a best return of 64.43% during her tenure. Li has a tenure of 7 years and 244 days, managing assets totaling 1.843 billion CNY, with a best return of 47.63% [3]

格隆汇11月3日丨科兴制药(688136.SH)公布，截至2025年10月31日，公司通过上海证券交易所交易系统 以集中竞价交易方式已累计回购公司股份131.93万股，占公司目前总股本比例为0.66%，回购成交的最 高价为43.50元/股，最低价为23.14元/股，支付的资金总额为人民币4,924.18万元（不含交易佣金等费 用）。 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-090 科兴生物制药股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在实施回购期间，应当在每个月的前 3 个交 易日内公告截至上月末的回购进展情况。现将公司回购股份的进展情况公告如下： 截至 2025 年 10 月 31 日，公司通过上海证券交易所交易系统以集中竞价交易 方式已累计回购公司股份 1,319,333 股，占公司目前总股本比例为 0.66%，回购成 交的最高价为43.50元/股，最低价为23.14元/股，支付的资金总额为人民币4,924.18 万元（不含交易佣金等费用）。 上述回购股份事项符合法律法规的规定及公司的回购股份方案。 三、其他事项 | 回购方案首次披露日 | 2025/3/19 | | | | | | | | --- | --- | --- | --- | --- ...

每经头条（nbdtoutiao）——"为了孩子吃上饭，自己只能靠喝水撑着"！美政府停摆危机逼近"临界 点"，4200万人吃饭成问题 每经AI快讯，科兴制药11月3日晚间发布公告称，截至2025年10月31日，公司通过上海证券交易所交易 系统以集中竞价交易方式已累计回购公司股份约132万股，占公司目前总股本比例为0.66%，回购成交 的最高价为43.5元/股，最低价为23.14元/股，支付的资金总额为人民币4924.18万元。 （记者 曾健辉） ...

Core Viewpoint - The announcement by Kexing Pharmaceutical regarding the completion of the first subject enrollment in the Phase I clinical trial of "GB18 Injection" marks a significant advancement in the company's commitment to innovative drug development, potentially offering new treatment hope for cancer cachexia patients [1][2]. Group 1: Product Development - "GB18 Injection" targets GDF15 (Growth Differentiation Factor 15) and is designed to treat cancer cachexia, a severe complication in cancer patients characterized by systemic metabolic disorders and progressive muscle and fat loss [2]. - The unique Fc fusion nanobody structure of "GB18 Injection" enhances drug stability and bioavailability while demonstrating strong inhibition of related downstream signaling pathways [2]. - Preclinical studies indicate that "GB18 Injection" can effectively reverse weight loss caused by cancer cachexia, significantly improve muscle and fat weight, and enhance the quality of muscle fibers in animal models [2]. Group 2: Market Potential - In 2022, there were 19.965 million new cases of malignant tumors globally, with 9.737 million deaths, indicating a growing patient population and a rapidly expanding market for cancer cachexia treatment [3]. - As a potential "First in Class" drug, "GB18" could fill the existing gap in the global market for cancer cachexia treatments, providing Kexing Pharmaceutical with a differentiated competitive advantage in the innovative drug sector [3]. Group 3: Strategic Direction - The ongoing Phase I clinical study of "GB18 Injection" aims to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in cancer cachexia patients [4]. - The progress of the GB18 project reflects Kexing Pharmaceutical's commitment to innovation, with increased investment in R&D and a focus on key breakthroughs in the global pharmaceutical market [4]. - The company is pursuing a dual reporting strategy in the U.S. and China, accelerating its transformation into an innovative multinational biopharmaceutical enterprise [4].

公告提到，年初至报告期末归属于上市公司股东的净利润较上年同期实现大幅增长，主要系： 一是欧盟市场销售带动海外收入大幅增长，同时公司持续开展营销端降本增效，销售费用下降；此外因 处置下属子公司及持有的私募基金公允价值变动带来非经常性损益金额增加。 近日，科兴制药公布2025年三季报，公司营业收入为11.5亿元，同比上升10.5%；归母净利润为1.11亿 元，同比上升547.7%；扣非归母净利润为7045万元，同比上升190.6%；经营现金流净额为-726万元，同 比下降113.6%；EPS(全面摊薄)为0.5528元。 其中第三季度，公司营业收入为4.47亿元，同比上升60.6%；归母净利润为3092万元，同比上升 483.3%；扣非归母净利润为2517万元，同比上升829.5%；EPS为0.1536元。 ...